Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study

Targeting SDF-1 in multiple myeloma tumor microenvironment

(2016) Juliette M.C. Bouyssou et al.   CANCER LETTERS

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

(2016) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

(2016) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit

(2015) Simon J. Harrison et al.   AMERICAN JOURNAL OF HEMATOLOGY

How I treat smoldering multiple myeloma

(2014) I. M. Ghobrial et al.   BLOOD

CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma

(2014) A. K. Azab et al.   BLOOD

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

(2014) Jesús F San-Miguel et al.   LANCET ONCOLOGY

SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy

(2014) Aldo M. Roccaro et al.   Cell Reports

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma

(2013) H. Ludwig et al.   BLOOD

Hematopoietic Stem and Progenitor Cell Mobilization in Mice and Humans by a First-in-Class Mirror-Image Oligonucleotide Inhibitor of CXCL12

(2013) A Vater et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma

(2013) M. A. Dimopoulos et al.   HAEMATOLOGICA

Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma

(2012) B. Arnulf et al.   HAEMATOLOGICA